PHK
AKRO

Point72 Hong Kong’s Akero Therapeutics AKRO Stock Holding History

Point72 Hong Kong’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-571
Closed -$23.1K – 446
2025
Q1 		$23.1K Buy
+571
New +$24.2K ﹤0.01% 397
2022
Q3 		– Sell
-398
Closed -$4K – 1894
2022
Q2 		$4K Sell
398
-1,844
-82% -$19.2K ﹤0.01% 1738
2022
Q1 		$32K Buy
+2,242
New +$39.3K ﹤0.01% 1442
2021
Q4 		– Sell
-650
Closed -$15K – 1847
2021
Q3 		$15K Sell
650
-2,073
-76% -$46.9K ﹤0.01% 1738
2021
Q2 		$68K Buy
2,723
+2,464
+951% +$69.2K ﹤0.01% 1402
2021
Q1 		$8K Sell
259
-336
-56% -$10.2K ﹤0.01% 1602
2020
Q4 		$15K Buy
595
+29
+5% +$807 ﹤0.01% 1473
2020
Q3 		$17K Buy
566
+202
+55% +$7.06K ﹤0.01% 900
2020
Q2 		$9K Buy
364
+334
+1,113% +$7.63K ﹤0.01% 989
2020
Q1 		$1K Sell
30
-302
-91% -$6.48K ﹤0.01% 863
2019
Q4 		$7K Buy
+332
New +$6.87K ﹤0.01% 1012
2019
Q3 		– Sell
-4,008
Closed -$77K – 968
2019
Q2 		$77K Buy
+4,008
New +$76K 0.02% 544

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Hong Kong's AKRO Position: Q2 2025 in Review

Point72 Hong Kong sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 571 shares — an estimated $23.1K sold.

Point72 Hong Kong first reported a position in AKRO in Q2 2019 and held it in 12 quarters. The position peaked at $77K in Q2 2019. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • Point72 Hong Kong reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 571 Akero Therapeutics shares in Q2 2025, an estimated $23.1K.
  • Point72 Hong Kong first reported a position in Akero Therapeutics in Q2 2019 and held it in 12 quarters.
  • Point72 Hong Kong's Akero Therapeutics position peaked at $77K in Q2 2019.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Point72 Hong Kong's 13F filing for Q2 2025, filed 14 Aug 2025.